MeiraGTx Awarded Target ALS Grant For Its NMD-Based Therapy for ALSIn The Media

MeiraGTx, a New York and UK based gene therapy company, announced today that it has been awarded a grant from Target ALS, a privately funded foundation bringing together a consortia of academic and biotech/pharmaceutical researchers focused on finding treatments for ALS patients. Target ALS is jointly funding this grant with the research organization ALS Finding A Cure®.
Read More

The ALS ONE Massachusetts ALS Partnership (MAP) Will Accelerate Treatment and Care in ALSIn The Media
The ALS Association today announced $2 million in funding to support ALS ONE-Massachusetts ALS Partnership (MAP), a partnership launched earlier this year among four institutional leaders in ALS treatment development: Massachusetts General Hospital (MGH), ALS Therapy Development Institute (ALS TDI), University of Massachusetts Medical School and Compassionate Care ALS (CCALS). The Association's contribution is in addition to $2 million from ALS Funding a Cure and $2 million from ALS ONE itself to support projects to help find treatments and a cure for amyotrophic lateral sclerosis (ALS).
Read More

Grand Challenge: Generation of a PET Tracer for TDP43 AggregatesIn The Media
A partnership between The ALS Association and ALS Finding a Cure®. Deadline for submission of Letter of Intent: March 22, 2016
Read More
Load More

Contact Us

A Program Of

Advisory Board

  • Leandro P. Rizzuto
  • Peter N. Foss
  • Merit  Cudkowicz, MD
  • Denis  Rizzuto
  • Stanley H. Appel, MD
  • Robert  Brown, D.Phil., MD
  • Tom  Gentile
  • Clive  Svendsen, PhD
  • Richard  Ellenbogen, MD
  • Randy  Fishman
  • Edward J. Rapp
  • Sudha  Maniam